Department of Cardiology, Inner Mongolia University for Nationalities Second Clinical Medical College, Lincheng Road, Yakeshi, 022150, China.
Ophthalmology Department, The Second Xiangya Hospital, Central South University, No. 139, Renmin Middle Road, Changsha, 410000, China.
BMC Immunol. 2022 Jun 4;23(1):28. doi: 10.1186/s12865-022-00502-7.
Enhancer of Zeste homologue 2 (EZH2) is a polycomb group gene and an epigenetic regulator that inhibits transcription, a modification associated with gene silencing. EZH2 plays an essential role in humoral and cell-mediated adaptive immunity. The purpose of the current study is to investigate the prognostic potential of EZH2 and to comprehensively analyse the correlation between EZH2 and immune infiltration in multiple cancer cases, especially liver hepatocellular carcinoma.
EZH2 expression across cancers was explored through Oncomine, HPA, and GEPIA2. Additionally, the prognostic value of EZH2 analysis across cancers was based on the GEPIA2, TCGA portal, Kaplan-Meier Plotter, and LOGpc databases. Based on GO and KEGG analyses, GSEA helped demonstrate the biological processes through which EZH2 might lead to HCC development. GEPIA and TIMER were adopted to detect the possible relationship of EZH2 expression with tumour-infiltrating immune cells (TIICs).
EZH2 overexpression levels were associated with poor prognosis of cancer, especially hepatocellular carcinoma. A high EZH2 expression level is related to a poor prognosis of HCC, especially in disease histology and stage III. The EZH2 expression level was positively correlated with critical gene markers of TAMs, M2 macrophages, M1 macrophages, and monocytes. Further analysis revealed that EZH2 genes were mainly related to DNA recombination, mitotic cell cycle phase transition, and chromosome segregation.
EZH2 plays an essential role in the immune microenvironment and is a potential prognostic marker and immunotherapy target for hepatocellular carcinoma.
EZH2 是多梳抑制复合物 2（polycomb group）基因和表观遗传调控因子，可抑制转录，这是一种与基因沉默相关的修饰。EZH2 在体液和细胞介导的适应性免疫中发挥着重要作用。本研究旨在探讨 EZH2 的预后潜力，并全面分析 EZH2 与多种癌症（尤其是肝癌）中免疫浸润的相关性。
通过 Oncomine、HPA 和 GEPIA2 数据库探讨 EZH2 在癌症中的表达情况。此外，还基于 GEPIA2、TCGA 数据库、Kaplan-Meier Plotter 和 LOGpc 数据库分析 EZH2 在癌症中的预后价值。通过 GO 和 KEGG 分析，GSEA 有助于展示 EZH2 可能导致 HCC 发展的生物学过程。采用 GEPIA 和 TIMER 检测 EZH2 表达与肿瘤浸润免疫细胞（TIICs）之间的可能关系。
EZH2 过表达水平与癌症预后不良相关，尤其是肝癌。高 EZH2 表达水平与 HCC 的不良预后相关，尤其是在疾病组织学和 III 期。EZH2 表达水平与 TAMs、M2 巨噬细胞、M1 巨噬细胞和单核细胞的关键基因标志物呈正相关。进一步分析表明，EZH2 基因主要与 DNA 重组、有丝分裂细胞周期相变和染色体分离有关。
EZH2 在免疫微环境中发挥着重要作用，是肝癌潜在的预后标志物和免疫治疗靶点。
